课题基金 / 基金详情

Automated, high-throughput identification of genetic structural variants for gene editing and undiagnosed genetic diseases screening

Automated, high-throughput identification of genetic structural variants for gene editing and undiagnosed genetic diseases screening
自动化、高通量鉴定遗传结构变异,用于基因编辑和未确诊遗传病筛查
批准号:
10080433
负责人:
Christopher John Tompkins
金额:
$108.82万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
2020
资助国家:
美国
项目状态:
已结题
起止时间:
2020-08-04 至 2022-07-31
关键词:
AlgorithmsAllelesAneuploidyArtificial IntelligenceBioinformaticsBiological AssayBiological MarkersBiomedical ResearchCRISPR screenCRISPR therapeuticsCRISPR/Cas technologyCell LineCell TherapyCellsChromatidsChromosomal RearrangementChromosome StructuresChromosomesClinicalClinical assessmentsClustered Regularly Interspaced Short Palindromic RepeatsColorComplexDNADNA Double Strand BreakDNA RepairDNA SequenceDataDetectionDevelopmentDiagnosisDiseaseDouble Strand Break RepairEventExposure toFingerprintFundingGenesGenetic DiseasesGenetic RecombinationGenetic StructuresGenome engineeringGenomic HybridizationsGenomicsGoalsGovernmentHumanImageImage AnalysisIn Situ HybridizationIndividualKnowledgeLocationMalignant NeoplasmsMapsMarketingMeasurementMeasuresMedicalMetabolismMethodsModernizationOncologyOutcomePaintPatternPattern RecognitionPharmacologic SubstancePhasePhenotypePolyploidyPopulationPrevalenceRadiationRare DiseasesReciprocal TranslocationResearchResearch PersonnelResolutionRiskSamplingSignal TransductionSister ChromatidSmall Business Innovation Research GrantSolidStructureSystemTechnologyTestingTherapeuticValidationVariantWorkautomated image analysisbasecellular engineeringclinically relevantcommercial applicationcomparative genomic hybridizationdensityexperimental studyfluorophoregene therapygenetic variantgenome editinggenomic profilesgenotoxicityhigh riskimprovedintelligent algorithmnew therapeutic targetpersonalized medicinereconstructionresearch and developmentscreeningstem cellsstructural genomicstechnological innovationtherapeutic genetherapeutic targettherapy developmenttoolwhole genome

项目摘要

项目成果

Christopher John Tompkins的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
ABSTRACT A simple method to comprehensively discover, characterize and identify structural variants arising from normal metabolic processes, as well as cell manipulations, would have great utility for gene editing, oncology, and rare disease research, among other applications. De Novo Directional Genomic Hybridization (dGH™) has been developed to efficiently screen thousands of cells for the presence of simple, complex, and heterogenous structural variants. In this project, Automated, High-Throughput Identification of Genetic Structural Variants for Gene Editing and Undiagnosed Genetic Diseases Screening, we propose K-Band™ dGH, an expanded dGH method. K-Band dGH is an in-situ hybridization method that utilizes high-density chromatid paints with bands of distinct spectra. A normal chromosome has a definitive pattern of bands, spectra and probe density. Structural variants are detected and identified via changes to the signal pattern. The proposed K-Band™ dGH method will provide the means for de novo discovery of balanced allelic translocations involving breakpoints at the same loci, inversions, and sister chromatid recombination and exchange events that are invisible to existing methods such as sequencing and aCGH. K-Band dGH will additionally characterize deletions, duplications, translocations, aneuploidy, polyploidy and more complex rearrangements. Structural variations cause a wide range of disorders, from rare diseases to cancers, and can be precise and definitive biomarkers. Also, because variations arise from the mis-repair of DNA double-strand breaks, unintended structural damage is an inevitable and potentially high-risk byproduct of genome editing. The potential of genome editing approaches such as CRISPR-Cas9 in the treatment of diseases is widely recognized and the realization of the promise of such therapeutic approaches will rely on accurate confirmation of the presence and absence of potentially risky structural variants. For these reasons, comprehensive detection and characterization of structural variations is a necessary step toward understanding, diagnosing and ultimately precisely treating genetic diseases. From a homogeneous or heterogenous population of cells, and in a single experiment, K-Band dGH will identify cells with a structurally normal phenotype, detect all classes of structural variants, and locate the breakpoints of all simple and complex structural variants in each cell. With a limit of detection below 5Kb, K-Band dGH is an ideal method for determining the outcomes of gene editing, discovering the causes of undiagnosed rare diseases, profiling genomic structural instability and variability, and discovering and validating previously unknown structural genetic drivers of disease.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
A comprehensive quality control testing strategy for engineered cells
  • 批准号:
    10330008
  • 项目类别:
  • 资助金额:
    $35.05万
  • 财政年份:
    2021
  • 负责人:
    Christopher John Tompkins
  • 依托单位:
Automated, high-throughput identification of genetic structural variants for gene editing and undiagnosed genetic diseases screening
  • 批准号:
    10228763
  • 项目类别:
  • 资助金额:
    $58.44万
  • 财政年份:
    2020
  • 负责人:
    Christopher John Tompkins
  • 依托单位:
海外基金